Viking's VK2809 is a drug with the very same mechanism of action, thus why I believe in this potential development path. It is my belief that an acquisition of this alone is a reduced risk event ...

Without an approved/marketed product in its portfolio, the focus is expected to be on updates related to Viking's pipeline consisting of three candidates — VK2735 (for obesity), VK2809 (for non ...

Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound ...